meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
progression or deaths (PFS)
deaths (OS)
mGC or mGEJC - M - HER2 neg/PDL1 positive
metastatic/advanced mGC or mGEJC
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
avelumab alone vs. Standard of Care (SoC)
1
certainty unassessable
+13%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open